Last reviewed 2026-04-23 · How we verify

HIP1601

HIP1601 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.

HIP1601 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes. Used for Type 2 diabetes mellitus.

At a glance

Mechanism of action

HIP1601 binds to and activates the glucagon-like peptide-1 (GLP-1) receptor on pancreatic beta cells, stimulating glucose-dependent insulin secretion. The drug also suppresses glucagon secretion and slows gastric emptying, collectively reducing postprandial and fasting blood glucose levels. Its extended half-life enables once-weekly or less frequent dosing.

Approved indications

• Type 2 diabetes mellitus

Common side effects

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Hypoglycemia

Key clinical trials

• Safety to Evaluate the Efficacy and Safety of HIP1601 in Patients With Non Erosive Reflux Disease (PHASE3)
• Food-effect on PK and PD of Single Oral Dose of HIP1601 in Healthy Subjects (PHASE1)
• Efficacy and Safety of HIP1601 Capsule (PHASE3)
• Food-effect on PK and PD of Single Oral Dose of HIP1601 in Healthy Male Subjects (PHASE1)
• Safety, Pharmacokinetics and Pharmacodynamics of the Two Esomeprazole Formulations (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• HIP1601 CI brief — competitive landscape report
• HIP1601 updates RSS · CI watch RSS
• Hanmi Pharmaceutical Company Limited portfolio CI